Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. (Q35173052)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Europe PubMed Central

Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Critical Reviews in Oncology Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

46 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

S21-31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanistic concepts in androgen-dependence of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of Apoptosis in Small-Cell Lung Cancer Cells by an Antisense Oligodeoxynucleotide Targeting the Bcl-2 Coding Sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900061-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1040-8428(03)00061-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850524%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35173052&oldid=2185989376"